The Lancet Growth Hormone Research: CJC-1295, GHRP-2, GHRP-6, and Growth Hormone Secretagogues

Lancet Insights | 2026-07-08 | 13 min read

Comprehensive analysis of growth hormone-releasing peptides including CJC-1295, GHRP-2, GHRP-6, and Ipamorelin, covering GHRH analogues, ghrelin pathway, and growth hormone secretagogue mechanisms.

Growth Hormone-Releasing Peptides: GHRH Analogues and Secretagogues

Research on growth hormone (GH) axis modulation has expanded significantly, with multiple peptide classes demonstrating effects on GH secretion. The Lancet has covered growth hormone research extensively, particularly regarding metabolic effects, body composition, and longevity applications. This analysis examines the key peptide classes: GHRH analogues (CJC-1295, Sermorelin, Tesamorelin) and growth hormone secretagogues (GHRP-2, GHRP-6, Ipamorelin).

Growth Hormone Axis Physiology

Hypothalamic Regulation

The growth hormone axis operates through a precisely regulated hierarchy:

  • **Hypothalamus**: Releases GHRH (growth hormone-releasing hormone) and somatostatin
  • **Anterior Pituitary**: Responds to GHRH/somatostatin to release GH
  • **Liver**: Produces IGF-1 in response to GH
  • **Peripheral tissues**: Respond to GH and IGF-1

Ghrelin Connection

The ghrelin axis provides an alternative GH-stimulating pathway:

  • Ghrelin is produced primarily by the stomach
  • Acts on GHSR-1a (growth hormone secretagogue receptor)
  • Potentiates GH release synergistically with GHRH
  • Creates appetite-stimulating effects

GHRH Analogues

CJC-1295

#### Structure

CJC-1295 is a GHRH analogue with strategic modifications:

Sequence: Tyr-D-Ala-Glp-Ala-Trp-D-Phe-Lys-NH2 (with DAC for CJC-1295)

The DAC (Drug Affinity Complex) modification enables albumin binding.

#### Pharmacology

CJC-1295 with DAC:

  • Half-life: 6-8 days
  • Increases GH levels for extended periods
  • Produces sustained IGF-1 elevation
  • Less physiological GH pulsatility

CJC-1295 without DAC:

  • Half-life: ~30 minutes
  • Mimics natural GHRH pulse patterns
  • More physiological GH secretion
  • Requires frequent dosing

#### Research Applications

CJC-1295 research includes:

  • GH deficiency models
  • Body composition studies
  • Wound healing research
  • Metabolic function assessment

Sermorelin

#### Structure

Sermorelin is a synthetic 29-amino acid fragment of GHRH:

Sequence: GHRH(1-29)-NH2 (Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2)

#### Characteristics

  • Near-full GHRH activity
  • Short half-life (~10-15 minutes)
  • Physiological GH release patterns
  • Well-tolerated in research

Tesamorelin

#### Structure

Tesamorelin is a synthetic GHRH analogue:

Sequence: Modified GHRH(1-44) with a trans-3-hexenoyl group

#### Clinical Applications

Tesamorelin has FDA approval for:

  • HIV-associated lipodystrophy
  • Abdominal fat reduction
  • Metabolic syndrome research

Growth Hormone Secretagogues

GHRP-2

#### Structure

GHRP-2 is a synthetic hexapeptide:

Sequence: D-Ala-D-β Nal-Ala-Trp-D-Phe-Lys-NH2

#### Characteristics

  • Potent GHSR-1a agonist
  • High efficacy in stimulating GH release
  • Increases prolactin and cortisol (mild)
  • Appetite-stimulating effects

#### Research Applications

  • GH stimulation studies
  • Body composition research
  • Muscle wasting models
  • Appetite regulation studies

GHRP-6

#### Structure

GHRP-6 is a synthetic hexapeptide:

Sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

#### Characteristics

  • Potent GH stimulator
  • Higher selectivity for GH than GHRP-2
  • Significant appetite stimulation
  • May affect cardiac function

Ipamorelin

#### Structure

Ipamorelin is a synthetic pentapeptide:

Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2

#### "Clean" Profile

Ipamorelin is distinguished by:

  • High GH efficacy
  • Minimal prolactin release
  • Minimal cortisol stimulation
  • Selective GHSR-1a activity
  • Good tolerability profile

Combination Protocols

CJC-1295 + GHRP-2/-6

The most researched combination approach:

Rationale:

  • CJC-1295: Sustained GHRH receptor activation
  • GHRP-2/6: Ghrelin receptor activation
  • Synergistic GH release through both pathways

Protocols:

  • Pulsatile: Short-acting compounds, frequent dosing
  • Sustained: CJC-1295 with DAC, GHRP-2/6 pre-bed
  • Research protocols vary significantly

Ipamorelin + CJC-1295

Alternative combination:

  • Lower side effect profile
  • Selective GH stimulation
  • Good for longer-term studies
  • Commonly used in research protocols

Research Considerations

Dosing Parameters

Research dosing ranges:

CJC-1295 with DAC:

  • 1-2 μg/kg (human equivalent)
  • 2-3 times per week
  • Cycle: 4-8 weeks

CJC-1295 without DAC:

  • 1-2 μg/kg
  • Daily or twice daily
  • Mimics pulsatile release

GHRP-2/6:

  • 1-2 μg/kg
  • 2-3 times daily
  • Often pre-bed for GH pulse

Ipamorelin:

  • 1-2 μg/kg
  • 2-3 times daily
  • Lower frequency than GHRP-2/6

Quality Standards

Rigorous GH research requires:

  • HPLC purity ≥99.5%
  • Mass spectrometry verification
  • Accurate weight/volume measurement
  • Batch-specific COA documentation
  • Proper storage (-20°C)

Quality Sourcing

Batch Consistency

Critical for research reproducibility:

  • Consistent peptide content
  • Verified sequence
  • Low impurity profiles
  • Batch-to-batch COA comparison

ZePeptide provides research-grade CJC-1295, GHRP-2, GHRP-6, Ipamorelin, Sermorelin, and Tesamorelin with complete analytical documentation for growth hormone research.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.

Research peptide catalogSupplier checklistMore peptide guides